SCHEMBL20892138

SCHEMBL20892138

CCc1ccnc(CN(CC)C(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 1/20 0.44
▸ NOS1 P29475 1/20 0.44
▸ NOS2 P35228 1/20 0.44
▸ PDGFRB P09619 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ CYP2D6 P10635 1/20 0.34
▸ KCNE1 P15382 1/20 0.34
▸ KCNA5 P22460 1/20 0.34
▸ POLB P06746 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ KDM5B Q9UGL1 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20909891 0.83 UHRF1 (0.38) NOS3NOS1NOS2PDGFRBKDR
SCHEMBL20889904 0.82 KDM4E (0.34) PDGFRBKDRCYP2D6KCNE1KCNA5
SCHEMBL18876636 0.80 KCNQ2 (0.39) NOS3NOS1NOS2PDGFRBKDR
SCHEMBL20889902 0.79 NOS3 (0.50) NOS3NOS1NOS2POLBTSHR
SCHEMBL18876832 0.79 LOX (0.47) NOS3NOS1NOS2PDGFRBKDR
SCHEMBL10240740 0.77 HSD17B10 (0.41) CYP2D6TSHRKDM4ETDP1CYP1A2
SCHEMBL17828159 0.77 NOS3 (0.52) NOS3NOS1NOS2CYP2D6POLB
SCHEMBL12088818 0.76 SMN1; SMN2 (0.52) CYP2D6KCNE1KCNA5POLBTSHR
SCHEMBL13343286 0.75 TDP1 (0.50) NOS3NOS1NOS2CYP2D6POLB
SCHEMBL218290 0.73 NOS3 (0.61) NOS3NOS1NOS2POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-04-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF WEE1, WEE2, NME1 NOS3 4089/4885NOS1 3906/4885NOS2 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback